Liquidia (NASDAQ:LQDA) Stock Gets Price Target Cut from Needham & Company LLC

Posted by Geri Gentry on Oct 17th, 2026

Liquidia (NASDAQ:LQDA – Free Report) had its price objective reduced by Needham & Company LLC from $72.00 to $58.00 in a research note released on Wednesday morning, MarketBeat.com reports. Needham & Company LLC currently has a buy rating on the stock.

LQDA has been the topic of a number of other reports. Royal Bank Of Canada set a $130.00 price target on shares of Liquidia in a report on Friday, July 24th. BTIG Research downgraded shares of Liquidia from a “buy” rating to a “neutral” rating in a research report on Thursday, October 1st. Piper Sandler set a $129.00 price objective on shares of Liquidia in a research note on Friday, July 24th. Raymond James Financial reiterated an “outperform” rating on shares of Liquidia in a research note on Thursday, October 8th. Finally, Lifesci Capital cut shares of Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 target price for the company. in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $72.85.

Read Our Latest Analysis on LQDA

Liquidia Trading Down 1.2%

Shares of NASDAQ LQDA opened at $34.35 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The stock has a market capitalization of $3.07 billion, a P/E ratio of 25.39, a price-to-earnings-growth ratio of 0.30 and a beta of 0.61. Liquidia has a 1-year low of $21.94 and a 1-year high of $93.61. The business has a fifty day moving average price of $60.09 and a 200 day moving average price of $61.54.

Liquidia (NASDAQ:LQDA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. During the same period in the previous year, the business earned ($0.49) EPS. Liquidia’s revenue for the quarter was up 1842.1% compared to the same quarter last year. Equities research analysts expect that Liquidia will post 2.05 EPS for the current fiscal year.

Insider Buying and Selling

In other Liquidia news, General Counsel Russell Schundler sold 13,692 shares of the company’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $389,948.16. Following the sale, the general counsel directly owned 602,841 shares of the company’s stock, valued at approximately $17,168,911.68. This represents a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sanjeev Khindri sold 1,101 shares of the stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $28.48, for a total value of $31,356.48. Following the sale, the insider directly owned 64,846 shares in the company, valued at $1,846,814.08. This represents a 1.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 745,194 shares of company stock valued at $41,081,702 in the last 90 days. 25.60% of the stock is currently owned by insiders.

Institutional Trading of Liquidia

Hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company raised its position in Liquidia by 63.3% during the first quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock valued at $2,199,000 after acquiring an additional 22,592 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Liquidia in the second quarter valued at approximately $29,694,000. Seven Fleet Capital Management LP boosted its position in Liquidia by 25.2% in the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after purchasing an additional 51,727 shares in the last quarter. Bank of America Corp DE boosted its position in Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares in the last quarter. Finally, Handelsbanken Fonder AB purchased a new stake in Liquidia in the 2nd quarter worth approximately $1,993,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

Positive Sentiment: Liquidia’s settlement with United Therapeutics resolves the litigation surrounding YUTREPIA, removing a major legal overhang and improving visibility for the product’s commercialization. The stock recently rallied sharply on the news, though the agreement is described as costly. Why Liquidia Is Up After YUTREPIA Litigation Settlement
Positive Sentiment: LifeSci Capital upgraded Liquidia to “Outperform” from “Market Perform,” reflecting increased confidence following the litigation resolution. LifeSci Capital Upgrades Liquidia
Positive Sentiment: BTIG Research raised Liquidia to “Buy,” adding to the bullish analyst commentary. HC Wainwright also maintained a “Buy” rating and lifted its price target to $65 from $58, implying substantial upside from recent trading levels.
Neutral Sentiment: Trading volume became unusually high after the analyst upgrades, indicating strong investor attention and repositioning following the settlement and rating changes. Liquidia Sees Unusually High Trading Volume
Negative Sentiment: Needham & Company reduced its price target for Liquidia, signaling that some analysts believe the stock’s valuation or the financial impact of the settlement warrants a more cautious outlook. Liquidia Price Target Cut by Needham

About Liquidia

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).